Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Egarter, M. Sator, P. Berghammer, J. Huber.
Efficacy, tolerability and rare side effects of tibolone treatment in postmenopausal women.
Int J Gynecol Obstet, 64 (1999), pp. 281-286
[2.]
M. Gambacciani, M. Ciaponi.
Postmenopausal osteoporosis management.
Curr Opin Obstet Gynecol, 12 (2000), pp. 189-197
[3.]
K.A. McKinney, W. Thompson.
A practical guide to prescribing hormone replacement therapy.
Drugs, 56 (1998), pp. 49-57
[4.]
Datos proporcionados por el Centro de Farmacovigilancia del País Vasco: información obtenida de la base de datos del Programa Internacional de Monitorización de Efectos Adversos a Medicamentos de la OMS en Uppsala, Suecia
[5.]
H. Adlercreutz, R. Tenhinen.
Some aspects of the interaction between natural and synthetic female sex hormones and the liver.
Am J Med, 49 (1970), pp. 630-648
[6.]
J.M. Metreau, D. Dhumeaux, P. Berthelot.
Oral contraceptives and the liver.
Digestion, 7 (1972), pp. 318-335
[7.]
R.A. Pérez-Mera, C.E. Shields.
Jaundice associated with norethindrone acetate therapy.
N Eng J Med, 267 (1962), pp. 1137-1139
[8.]
A.D. Langlands, V.M. Martin.
Jaundice associated with norethisterone acetate treatment of breast cancer.
Lancet, 1 (1975), pp. 584-585
[9.]
H.J. Zimmerman.
Hormonal derivatives and related drugs. En: Hepatotoxicity.
The adverse effects of drugs and other chemicals in the liver (2nd ed.), pp. p555-p588
[10.]
K.G. Ishack, H.J. Zimmerman.
Hepatotoxic effects of the anabolic/ androgenic steroids.
Semin Liver Dise, 7 (1987), pp. 230-236
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
